Ph+ Leukemias in 2009 and beyond

Transcript

1 Ph+ Leukemias in 2009 and beyond Turin, th March 2009 Centro Congressi TORINO INCONTRA Via Nino Costa, Torino With an unrestricted educational grant from

2 Scientific Committee: G. Alimena, M. Baccarani, AM. Carella, R. Foà, G. Martinelli, E. Morra, F. Pane, G. Rosti, G. Saglio, G. Specchia Faculty Abruzzese Elisabetta (Roma) Aglietta Massimo (Torino) Alimena Giuliana (Roma) Arcese William (Roma) Baccarani Michele (Bologna) Boccadoro Mario (Torino) Bocchia Monica (Siena) Bosi Alberto (Firenze) Breccia Massimo (Roma) Carella Angelo Michele (Genova) Castagnetti Fausto (Bologna) Cervantes Francisco (Barcelona) Chisesi Teodoro (Venezia) Cilloni Daniela (Orbassano TO) Cuneo Antonio (Ferrara) Fagioli Franca (Torino) Fava Carmen (Orbassano TO) Ferrara Felicetto (Napoli) Ferrero Dario (Torino) Foà Robin (Roma) Gambacorti-Passerini Carlo (Monza) Goldman John (London) Gozzini Antonella (Firenze) Hehlmann Rudigher (Mannheim) Hochhaus Andreas (Mannheim) Lambertenghi Deliliers Giorgio (Milano) Latagliata Roberto (Roma) Lauria Francesco (Siena) Le Coutre Philipp (Berlin) Levis Alessandro (Alessandria) Liberati Marina (Perugia) Liso Vincenzo (Bari) Lo Coco Francesco (Roma) Martinelli Giovanni (Bologna) Martino Bruno (Reggio Calabria) Morra Enrica (Milano) Ottmann Oliver (Frankfurt) Pane Fabrizio (Napoli) Petrini Mario (Pisa) Pizzolo Giovanni (Verona) Pregno Patrizia (Torino) Pungolino Ester (Milano) Radaelli Franca (Milano) Rege Cambrin Giovanna (Torino) Ribera Josè Maria (Barcelona) Rodeghiero Francesco (Vicenza) Rosti Gianantonio (Bologna) Russo Domenico (Brescia) Saglio Giuseppe (Torino) Santini Valeria (Firenze) Soverini Simona (Bologna) Specchia Giorgina (Bari) Stagno Fabio (Catania) Tarella Corrado (Torino) Tiribelli Mario (Udine) Ulisciani Stefano (Orbassano TO) Vigneri Paolo (Catania) Vitolo Umberto (Torino)

3 Ph+ Leukemias in 2009 and beyond SCIENTIFIC PROGRAM Friday, 27 th March Welcome: M. Baccarani, F. Pane, G. Saglio FIRST SESSION: UPDATE ON BIOLOGY OF CML AND PH-POSITIVE LEUKEMIAS Chairmen: F. Lauria, F. Rodeghiero Coffee break Fishing genes involved in CML progression (D. Cilloni) Molecular mechanisms leading to genomic instability of the Ph+ leukemias (G. Martinelli) Lecture: CML management in 2009: what s new? (M.Baccarani) Chairmen: R. Hehlmann, G. Lambertenghi Deliliers SECOND SESSION: PROBLEMS IN FIRST LINE THERAPY OF CML Chairmen: A. Levis, M. Petrini Resistance to imatinib (G. Saglio) What s new about BCR-ABL mutations (S. Soverini) CML monitoring in usual clinical practice: which is the situation in Italy? (E. Morra) Suboptimal response (interactive case) (C. Fava) Failure due to mutations (interactive case) (F. Pane) Imatinib forever after MMR achievement? (AM. Carella) Immuno-therapy in CML: feasibility and results (M. Bocchia) Saturday, 28 th March THIRD SESSION: SECOND LINE THERAPY OF CML Chairmen: M. Boccadoro, U. Vitolo Imatinib high dose: still an option? (G. Rosti) Update on studies with Dasatinib (V. Santini) Update on studies with Nilotinib (G. Rege Cambrin) Update on studies with Bosutinib (C. Gambacorti-Passerini)

4 Lecture: Choice of second line therapy: when and what (F. Cervantes) Chairmen: Chairman: M. Baccarani, C. Tarella Coffee break FOURTH SESSION: PH+ ALL Chairmen: G. Alimena, F. Ferrara Lunch time German experience and future approach (O. Ottmann) Italian experience and future approach (R. Foà) Spanish experience and future approach (JM. Ribera) MD Anderson experience and future approach (C. Fava) Japanese experience (D. Russo) FOURTH SESSION: PH+ ALL (second part) Ph+ ALL: Summary and considerations (R. Foà, J. Goldman) Round table between all speakers leaded and coordinated by R. Foà, J. Goldman FIFTH SESSION: STEM CELL TRANSPLANTATION (SCT) FOR CML IN THE TKIS ERA Chairmen: A. Bosi, A. Cuneo Coffee break Which SCT and and when in CML in the TKI era (W. Arcese) Results of SCT in Germany in the TKIs era (R. Helhmann) BMT in pediatric Ph+ ALLs (F. Fagioli) SIXTH SESSION: THERAPY OF CML ADVANCED PHASES Chairmen: M. Liberati, G. Pizzolo Efficacy of Dasatinib in CML AP and BC (G. Specchia) Efficacy of Nilotinib in CML AP and BC (P. Vigneri) CML AP treatment (interactive case) (F. Radaelli) CML BC treatment (interactive case) (F. Castagnetti) Elderly Ph+ ALL treatment (Interactive case) (E. Abruzzese) Adult Ph+ ALL treatment (Interactive case) (B. Martino)

5 Sunday, 29 th March SEVENTH SESSION: PRACTICAL MANAGEMENT OF TOXICITY IN CML PATIENTS TREATED WITH TKIS Chairmen: T. Chisesi, V. Liso Coffee break Efficacy of Dasatinib in elderly (R. Latagliata) Pregnancy and CML (S. Ulisciani) Cardiac toxicity (interactive case) (P. Pregno) Liver toxicity (interactive case) (D. Ferrero) Hyperglycemia (interactive case) (M. Breccia) Cutaneous rash (interactive case) (F. Stagno) Pancreatic toxicity (interactive case) (E. Pungolino) Gastrointestinal intolerance (interactive case) (A. Gozzini) Fluid retention (interactive case) (M. Tiribelli) EIGHTH SESSION: PERSPECTIVES FOR THE FUTURE OF CML Chairmen: M. Aglietta, F. Lo Coco Special lectures: Solved and unsolved problems in biological research in CML (J. Goldman) Solved and unsolved problems in clinical research (A. Hochhaus) Perspective for the treatment of CML in different areas of the world (P. Le Coutre) The importance of a European coordinated approach: the example and the experience of the European Investigators on CML (R. Helhmann) CONCLUSIONS M. Baccarani, F. Pane, G. Saglio With an unrestricted educational grant from

6 Scientific and Organizing Secretariat IntraMed Communications Srl Tel Fax CME Continuing Medical Education (CME) has been applied for this meeting. Venue Centro Congressi Torino Incontra Via Nino Costa, Torino With an unrestricted educational grant from